Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden

Myelofibrosis (MF) has heterogeneous clinical manifestations, with some patients exhibiting a myelodepletive phenotype characterized by cytopenias and an absent or low JAK2V617F allele burden. Ruxolitinib may be less effective in these patients. We assessed the efficacy of pacritinib, a JAK2/IRAK1 i...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood Adv
Главные авторы: Tremblay, Douglas, Mesa, Ruben, Scott, Bart, Buckley, Sarah, Roman-Torres, Karisse, Verstovsek, Srdan, Mascarenhas, John
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2020
Предметы:
Myeloid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724916/
https://ncbi.nlm.nih.gov/pubmed/33275766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002970
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы